-
Phase 3 clinical results of C3 complement inhibitors for the treatment of age-related macular degeneration released
Time of Update: 2021-11-05
On September 9, Apellis announced the top-line results obtained in two phase 3 clinical trials, DERBY and OAKS, in the research pegcetacoplan targeting the complement C3 protein .
com/news-release/2021/09/09/2294782/0/en/Apellis-Announces-Top-Line-Results-from-Phase-3-DERBY-and-OAKS-Studies-in-Geographic-Atrophy-GA -and-Plans-to-Submit-NDA-to-FDA-in-the-First-Half-of-2022.
-
New medicine for rare diseases! C3 inhibitor pegcetacoplan received FDA priority review: Phase 3 efficacy beats heavyweight C5 inhibitor Soliris
Time of Update: 2020-11-28
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a new drug application (NDA) for Pgcetacoplan (APL-2), a drug used to treat cystic sleep hemoglobinuria (PNH), which has been shown in clinical trials to raise PNH standards and hopefully redefine PNH treatment.
-
for listing: head-to-head phase 3 efficacy beats heavyweight C5 inhibitor Soliris.
Time of Update: 2020-10-07
16, 2020 // -- Apellis Pharmaceuticals is committed to developing pioneering and best-in-class therapies through a groundbreaking targeted C3 approach to treat a wide range of diseases driven by uncontrolled or overactivated complement cascading reactions, including hematology, ophthalmology and nephrology.
-
Better than approved therapy Innovation C3 complementary therapy key phase 3 clinical results positive
Time of Update: 2020-07-09
On the 13th, Apellis Pharmaceuticals announced the detailed results of the C3 complementary targeted therapy pegcetacoplan, developed by the company at the 25th annual meeting of the European Society